Opinions and Concerns Surrounding Long-Acting Injectable (LAI) and Oral HIV Pre-exposure Prophylaxis (PrEP) Among Current and Former LAI and Oral PrEP Users

IF 2.4 2区医学 Q2 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH

AIDS and Behavior Pub Date : 2025-06-17 DOI:10.1007/s10461-025-04749-0

Alice K. Schaack, Maxwell B. Allamong, Frances Hung, Richard T. Barfield, Sarah M. Wilson, Tina Watkins, Katherine Link, Mehri S. McKellar

{"title":"Opinions and Concerns Surrounding Long-Acting Injectable (LAI) and Oral HIV Pre-exposure Prophylaxis (PrEP) Among Current and Former LAI and Oral PrEP Users","authors":"Alice K. Schaack, Maxwell B. Allamong, Frances Hung, Richard T. Barfield, Sarah M. Wilson, Tina Watkins, Katherine Link, Mehri S. McKellar","doi":"10.1007/s10461-025-04749-0","DOIUrl":null,"url":null,"abstract":"<div><p>Long-acting injectable (LAI) pre-exposure prophylaxis (PrEP) has potential to increase PrEP uptake and adherence. However, most studies investigating opinions about LAI PrEP were done prior to its approval. We administered a cross-sectional electronic survey to clients at an urban PrEP clinic in the U.S. South. Eligible participants were 18 + and had previously taken or been prescribed oral or LAI PrEP. They were asked their opinions on PrEP, barriers to access, perceived HIV risk, and PrEP stigma. Between January and April 2024, 123 people participated. Twenty-two (17.9%) used LAI PrEP, 80 (65.0%) oral PrEP, and 21 (17.1%) were not currently using PrEP. Most participants identified as men (87.8%), and mean age was 38.6 (range 19–78). Participants were 52.8% White, 27.6% Black, and 14.6% Latinx. 56.1% preferred injection versus daily oral pill. Common concerns about PrEP included side effects (<i>n</i> = 48), cost of medication (<i>n</i> = 21), and cost of clinic visits/tests (<i>n</i> = 21). Of those taking oral PrEP, 56.3% reported remaining on oral because LAI was not offered to them and/or they were not aware of it. Perceived HIV risk scores were on average higher for those not currently taking PrEP (not on = 26.8, SD = 6.54; LAI = 22.3, SD = 6.45; oral = 24.2, SD = 6.13). Overall, participants had low to moderate PrEP stigma scores. Despite majority preference for LAI PrEP, patients are frequently unaware of or not offered LAI. Common concerns about PrEP include side effects and costs. These data demonstrate the importance of improving LAI PrEP awareness and accessibility of choice.</p></div>","PeriodicalId":7543,"journal":{"name":"AIDS and Behavior","volume":"29 10","pages":"3026 - 3035"},"PeriodicalIF":2.4000,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s10461-025-04749-0.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"AIDS and Behavior","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s10461-025-04749-0","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}

引用次数: 0

Abstract

Long-acting injectable (LAI) pre-exposure prophylaxis (PrEP) has potential to increase PrEP uptake and adherence. However, most studies investigating opinions about LAI PrEP were done prior to its approval. We administered a cross-sectional electronic survey to clients at an urban PrEP clinic in the U.S. South. Eligible participants were 18 + and had previously taken or been prescribed oral or LAI PrEP. They were asked their opinions on PrEP, barriers to access, perceived HIV risk, and PrEP stigma. Between January and April 2024, 123 people participated. Twenty-two (17.9%) used LAI PrEP, 80 (65.0%) oral PrEP, and 21 (17.1%) were not currently using PrEP. Most participants identified as men (87.8%), and mean age was 38.6 (range 19–78). Participants were 52.8% White, 27.6% Black, and 14.6% Latinx. 56.1% preferred injection versus daily oral pill. Common concerns about PrEP included side effects (n = 48), cost of medication (n = 21), and cost of clinic visits/tests (n = 21). Of those taking oral PrEP, 56.3% reported remaining on oral because LAI was not offered to them and/or they were not aware of it. Perceived HIV risk scores were on average higher for those not currently taking PrEP (not on = 26.8, SD = 6.54; LAI = 22.3, SD = 6.45; oral = 24.2, SD = 6.13). Overall, participants had low to moderate PrEP stigma scores. Despite majority preference for LAI PrEP, patients are frequently unaware of or not offered LAI. Common concerns about PrEP include side effects and costs. These data demonstrate the importance of improving LAI PrEP awareness and accessibility of choice.

查看原文本刊更多论文

目前和以前长效注射（LAI）和口服HIV暴露前预防（PrEP）使用者的意见和关注

长效注射（LAI）暴露前预防（PrEP）有可能增加PrEP的吸收和依从性。然而，大多数调查人们对LAI PrEP看法的研究都是在其批准之前进行的。我们对美国南部一家城市PrEP诊所的客户进行了一项横断面电子调查。符合条件的参与者为18岁以上，以前服用或处方口服或LAI PrEP。他们被问及对PrEP、获取障碍、感知的艾滋病毒风险和PrEP耻辱的看法。在2024年1月至4月期间，123人参与了这项研究。22人（17.9%）使用LAI PrEP， 80人（65.0%）使用口服PrEP， 21人（17.1%）目前未使用PrEP。大多数参与者为男性（87.8%），平均年龄38.6岁（范围19-78岁）。参与者中白人占52.8%，黑人占27.6%，拉丁裔占14.6%。56.1%的人更喜欢注射，而不是每天口服药片。对PrEP的常见担忧包括副作用（n = 48）、药物费用（n = 21）和门诊就诊/检查费用（n = 21）。在服用口服PrEP的人中，56.3%的人报告说，由于没有向他们提供LAI和/或他们不知道这一点，他们继续服用口服PrEP。目前未服用PrEP者的感知艾滋病毒风险评分平均较高(未on = 26.8, SD = 6.54；Lai = 22.3, sd = 6.45；口腔= 24.2,SD = 6.13)。总体而言，参与者的PrEP污名得分低至中等。尽管大多数人倾向于LAI PrEP，但患者往往不知道或未提供LAI。对PrEP的常见担忧包括副作用和费用。这些数据表明提高LAI PrEP意识和选择可及性的重要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

AIDS and Behavior Multiple-

CiteScore

6.60

自引率

13.60%

发文量

382

期刊介绍： AIDS and Behavior provides an international venue for the scientific exchange of research and scholarly work on the contributing factors, prevention, consequences, social impact, and response to HIV/AIDS. This bimonthly journal publishes original peer-reviewed papers that address all areas of AIDS behavioral research including: individual, contextual, social, economic and geographic factors that facilitate HIV transmission; interventions aimed to reduce HIV transmission risks at all levels and in all contexts; mental health aspects of HIV/AIDS; medical and behavioral consequences of HIV infection - including health-related quality of life, coping, treatment and treatment adherence; and the impact of HIV infection on adults children, families, communities and societies. The journal publishes original research articles, brief research reports, and critical literature reviews. provides an international venue for the scientific exchange of research and scholarly work on the contributing factors, prevention, consequences, social impact, and response to HIV/AIDS. This bimonthly journal publishes original peer-reviewed papers that address all areas of AIDS behavioral research including: individual, contextual, social, economic and geographic factors that facilitate HIV transmission; interventions aimed to reduce HIV transmission risks at all levels and in all contexts; mental health aspects of HIV/AIDS; medical and behavioral consequences of HIV infection - including health-related quality of life, coping, treatment and treatment adherence; and the impact of HIV infection on adults children, families, communities and societies. The journal publishes original research articles, brief research reports, and critical literature reviews.5 Year Impact Factor: 2.965 (2008) Section ''SOCIAL SCIENCES, BIOMEDICAL'': Rank 5 of 29 Section ''PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH'': Rank 9 of 76